2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions

View by Date

Saturday, October 6, 2018

1:45pm-3:15pm: Novel biomarkers of autonomic regulation and sleep in Parkinson’s Disease derived from Network Physiology

O. Vaou, P. Ivanof, A. DePold-Hohler, F. Lombardi, R. Endalatpour, A. Quaicoe (Boston, MA, USA)

Neurophysiology (Non-PD) · Hall 3FG

1:45pm-3:15pm: Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys

T. Kitajima, M. Bonifácio, P. Moser, P. Soares-da-Silva, M. Tanaka (Osaka, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches

S. Iqbal (Chennai, India)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Novel missense variants in KMT2B in segmental dystonia

J. Ma, X.H. Wan (Beijing, China)

Genetics (Non-PD) · Hall 3FG

1:45pm-3:15pm: Objective analysis of walking tremor in Parkinson’s disease: A spectrum of classical rest tremor?

N. Dadphan, O. Jitkritsadakul, C. Anan, R. Bhidayasiri (Bangkok, Thailand)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Objective Predictors of ‘Early Tolerance’ to Ventral Intermediate nucleus of thalamus DBS In Essential Tremor Patients

S. Merchant, S. Kuo, S. Pullman, B. Ford (Bethesda, MD, USA)

Neurophysiology (Non-PD) · Hall 3FG

1:45pm-3:15pm: Occurrence of dopaminergic adverse-events in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

K. Chaudhuri, A. Sauerbier, J. Ferreira, F. Stocchi, E. Arbe, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Occurrence of dopaminergic adverse-events in patients that switched from entacapone to opicapone: The BIPARK-I open-label experience

A. Ceballos-Baumann, K. Eggert, J. Ferreira, W. Poewe, O. Rascol, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Munich, Germany)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG

1:45pm-3:15pm: Ocular motor function in stiff person syndrome – Role of GABA and beyond

F. Wang, L. Neilson, H. Wang, G. Wilmot, A. Shaikh (Cleveland, OH, USA)

Pathophysiology (Other Movement Disorders) · Hall 3FG

1:45pm-3:15pm: ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects

J. Tuunainen, J. Ellmén, M. Vahteristo, A. Holopainen, D. Strugala (Espoo, Finland)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment · Hall 3FG